Karyopharm Posts Q1 Revenue Growth, Cuts Loss to $22.4M, Completes EC042 Enrollment
KPTI•Karyopharm Therapeutics saw Q1 revenue growth from favorable gross-to-net dynamics and reduced its net loss to $22.4 million while securing additional financing. Its Phase III SENTRY myelofibrosis trial delivered rapid, deep spleen volume reductions but failed symptom significance, and EC042 enrollment for endometrial cancer is complete with data due mid-2026.
1. Q1 Financial Results and Liquidity
In Q1 2026, Karyopharm reported net product revenue growth driven by favorable gross-to-net dynamics, although underlying demand for XPOVIO declined versus the prior year due to new competition. The company posted a net loss of $22.4 million, an improvement from the previous year, and secured additional financing to bolster liquidity.
2. SENTRY Myelofibrosis Trial Update
The Phase III SENTRY trial of selinexor combined with ruxolitinib demonstrated rapid, deep, and sustained spleen volume reductions but did not achieve statistical significance for symptom improvement at week 24. The company is evaluating 23 reported deaths in the placebo arm and plans to discuss next steps with the FDA over the coming quarters.
3. Pipeline Progress and Commercial Strategy
Enrollment is complete in the EC042 trial for endometrial cancer, with top-line results expected in mid-2026. Karyopharm has strengthened its commercial capabilities and relationships, positioning itself for potential product launches in myelofibrosis and endometrial cancer.
